Cannabis Bioscience International Holdings, Inc. / "Long-term" | Tables in SEC filings

CBIH Cannabis Bioscience International Holdings, Inc.

Quarterly report (amended)

CONSOLIDATED BALANCE SHEETS


	November 30, 2024		May 31, 2024
	(Unaudited)		(Audited)

ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	1,002	$	755
Accounts receivable		13,819		20,139
Other current assets		598		598
TOTAL CURRENT ASSETS		15,419		21,492
Right-of-use asset		19,347		35,670
TOTAL ASSETS	$	34,766	$	57,162

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	166,119	$	196,088
Bank overdraft		2,236		2,408
Related party payables		559,488		503,214
Short-term loans (net of amortization of loan fees)		112,629		151,267
SBA loan - current		14,592		7,054
Lease liabilities - current		17,610		21,877
TOTAL CURRENT LIABILITIES		872,674		881,908

LONG-TERM LIABILITIES
Notes payable		77,437		–
SBA loan		249,500		249,361
Lease liabilities		–		4,906
TOTAL LONG-TERM LIABILITIES		326,937		254,267
TOTAL LIABILITIES		1,199,611		1,136,175

STOCKHOLDERS’ DEFICIENCY
Authorized 10,000,000 shares of preferred stock, without par value, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock and 2,000 shares have been designated Series B Preferred Stock (2,000 and 1,000 shares outstanding at November 30, 2024, and May 31, 2024, respectively		–		–
Common Stock, without par value: 20,000,000,000 shares authorized; 10,506,749,347 and 10,431,749,347 shares issued and outstanding at November 30, 2024, and May 31, 2024, respectively.		–		–
Additional paid-in capital		4,325,068		4,255,068
Accumulated deficit		(5,489,913)		(5,334,081)
TOTAL STOCKHOLDERS’ DEFICIENCY		(1,164,845)		(1,079,013)

TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	34,766	$	57,162


	February 29, 2024		May 31, 2023
	(Unaudited)		(Audited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents	$	794	$	8,913
Accounts receivable		17,041		10,549
Related party receivables		–		–
Other current assets		598		–
TOTAL CURRENT ASSETS		18,433		19,462
Right-of-use asset, net of accumulated depreciation		75,541		23,920
TOTAL ASSETS	$	93,974	$	43,382

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES
Accounts payable and accrued expenses	$	257,527	$	111,299
Overdraft		5,485		–
Deferred revenue		–		28,641
Related party payables		323,678		105,173
Short-term loan		151,267		121,407
SBA loan – current		7,054		14,592
PPP loan		–		–
Lease liabilities – current		56,039		4,435
TOTAL CURRENT LIABILITIES		801,049		385,547

LONG-TERM LIABILITIES
SBA loan – noncurrent		249,500		249,500
Lease liabilities – noncurrent		19,502		–
TOTAL LONG-TERM LIABILITIES		269,002		249,500
TOTAL LIABILITIES		1,070,052		635,047

STOCKHOLDERS’ DEFICIENCY
Authorized 10,000,000 shares of preferred stock, of which 2,500,000 shares have been designated Series A Convertible Preferred Stock and issued and 1,000 shares have been designated Series B Preferred Stock and issued		–		–
Common stock, without par value: 20,000,000,000 shares authorized; 10,431,749,347 and 10,059,677,919 shares issued and outstanding at February 29, 2024, and May 31, 2023, respectively.		–		–
Additional paid-in capital		4,222,068		4,091,071
Accumulated deficit		(5,198,146)		(4,682,736)
TOTAL STOCKHOLDERS’ DEFICIENCY		(976,078)		(591,665)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$	93,974	$	43,382

Table search / Cannabis Bioscience International Holdings, Inc. / "Long-term"